WHO calls for a central registry of all gene editing research conducted worldwide

It would be irresponsible for any scientist to conduct human gene-editing studies in people, and a central registry of research plans should be set up to ensure transparency, World Health Organization experts said on 19 March. After its first two-day meeting in Geneva, the WHO panel of gene editing experts — which was established in December after a **Chinese scientist said he had edited the genes** of twin babies — said it had agreed on a framework for setting future standards. It said a central registry of all human genome editing research was needed “in order to create an open and transparent database of ongoing work”, and asked the WHO to start setting up such a registry immediately. [caption id=“attachment_6297151” align=“alignnone” width=“1280”] A logo is pictured on the World Health Organization (WHO) headquarters in Geneva. Image: Reuters[/caption] “The committee will develop essential tools and guidance for all those working on this new technology to ensure maximum benefit and minimal risk to human health,” Soumya Swamanathan, the WHO’s chief scientist, said in a statement. A Chinese scientist last year claimed to have edited the genes of twin baby girls. News of the births prompted global condemnation, in part because it raised the ethical spectre of so-called “designer babies” — in which embryos can be genetically modified to produce children with desirable traits.

Live from Geneva with Dr Margaret Ann Hamburg, Co-Chair of the WHO Expert Advisory Committee on Human Genome Editing https://t.co/QShfib3UxW

— World Health Organization (WHO) (@WHO) March 19, 2019

Top scientists and ethicists from seven countries called last week for a global moratorium on gene editing of human eggs, sperm or embryos that would result in such genetically-altered babies — saying this “could have permanent and possibly harmful effects on the species”. The WHO panel’s statement said any human gene-editing work should be done for research only, should not be done in human clinical trials, and should be conducted transparently. “It is irresponsible at this time for anyone to proceed with clinical applications of human germline genome editing.” The WHO’s director-general, Tedros Adhanom Ghebreyesus, welcomed the panel’s initial plans. “Gene editing holds incredible promise for health, but it also poses some risks, both ethically and medically,” he said in a statement. The committee said it aims over the next two years to produce “a comprehensive governance framework” for national, local and international authorities to ensure human genome editing science progresses within agreed ethical boundaries.